[ Inside the business ]

LLY stock analysis

LLY · Eli Lilly & Co

Pharmaceutical preparations. Growing 39%.

Watch: growth that has stopped speeding up.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?In-body cell therapy · 2.8×
'20'21'22'23'24'2514
#8 of 20 mentioning it
03 Will customers keep buying?Sales +39%, steady
No customer over 10%
Prepaid $166MSales +39%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 77% → 83%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −0.2%/yrDebt $49.5B
07 What could break it?1 to watch
  • Growth slowing

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +56%, +48%, then +39% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.4× the market. In the 2008 crisis it fell 42% while the market fell 51%. Debt is moderate.

Speculative check

Not classified.

Not Self-funding because of: debt over 4× operating profit.

What they sell

93% Product.

Product 93% · Collaboration and Other Revenue 7%

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Early maturity.

It earns cash, still invests, and pays back more than it borrows. Unusually, sales are still growing like a young company's.

Earnings quality

Some warning signs.

A few of its numbers drift toward the pattern of past manipulators. Cash covers 111¢ of each $1 of profit.

Competitive advantage

Not measurable.

Returns on capital can't be computed from its filings (common for banks and insurers).

Future bets

18% on research.

$15.4B a year on R&D.

All figures from Eli Lilly & Co's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.